Search

Your search keyword '"Djimde A"' showing total 25 results
Start Over Author "Djimde A" Journal bmj global health
25 results on '"Djimde A"'

1. PS-003: EVIDENCE-INFORMED POLICY MAKING: CHALLENGES AND OPPORTUNITIES

Author

Makanga, Michael, Beattie, Pauline, Breugelmans, Gabrielle, Nyirenda, Thomas, Bockarie, Moses, Tanner, Marcel, Volmink, Jimmy, Hankins, Catherine, Walzl, Gerhard, Chegou, Novel, Malherbe, Stephanus, Hatherill, Mark, Scriba, Thomas J., Zak, Daniel E., Barry, Clifton E., Kaufmann, Stefan H.E., Noor, Abdisalan, Strub-Wourgaft, Nathalie, Phillips, Patrick, Munguambe, Khátia, Ravinetto, Raffaella, Tinto, Halidou, Diro, Ermias, Mahendrahata, Yodi, Okebe, Joseph, Rijal, Suman, Garcia, Coralith, Sundar, Shyam, Ndayisaba, Gilles, Sopheak, Thai, Ngoduc, Thang, Loen, Harry Van, Jacobs, Jan, D'Alessandro, Umberto, Boelaert, Marleen, Buvé, Anne, Kamalo, Patrick, Manda-Taylor, Lucinda, Rennie, Stuart, Mokgatla, Boitumelo, Bahati, Prince, Ijsselmuiden, Carel, Afolabi, Muhammed, Mcgrath, Nuala, Kampmann, Beate, Imoukhuede, Egeruan, Alexander, Neal, Larson, Heidi, Chandramohan, Daniel, Bojang, Kalifa, Kasaro, Margaret Phiri, Muluka, Brenda, Kaunda, Kaunda, Morse, Jill, Westfall, Andrew, Kapata, Nathan, Kruuner, Annika, Henostroza, German, Reid, Stewart, Alabi, Abraham, Foguim, Francis, Sankarganesh, Jeyaraj, Bruske, Ellen, Mfoumbi, Arnault, Mevyann, Chester, Adegnika, Ayola, Lell, Bertrand, Kranzer, Katharina, Kremsner, Peter, Grobusch, Martin, Sabiiti, Wilber, Ntinginya, Nyanda, Kuchaka, Davis, Azam, Khalide, Kampira, Elizabeth, Mtafya, Bariki, Bowness, Ruth, Bhatt, Nilesh, Davies, Gerry, Kibiki, Gibson, Gillespie, Stephen, Lejon, Veerle, Ilboudo, Hamidou, Mumba, Dieudonné, Camara, Mamady, Kaba, Dramane, Lumbala, Crispin, Fèvre, Eric, Jamonneau, Vincent, Bucheton, Bruno, Büscher, Philippe, Chisenga, Caroline, Sinkala, Edford, Chilengi, Roma, Chitundu, Hellen, Zyambo, Zude, Wandeler, Gilles, Vinikoor, Michael, Emilie, Dama, Camara, Oumou, Mathurin, Koffi, Guiguigbaza-Kossigan, Dayo, Philippe, Büscher, Regassa, Fikru, Hassane, Sakande, Bienvenu, Somda Martin, Fabrice, Courtin, Ouédraogo, Elie, Kouakou, Lingue, Owusu, Michael, Mensah, Eric, Enimil, Anthony, Mutocheluh, Mohamed, Ndongo, Francis Ateba, Tejiokem, Mathurin Cyrille, Texier, Gaetan, Penda, Calixte, Ndiang, Suzie, Ndongo, Jean-Audrey, Guemkam, Georgette, Sofeu, Casimir Ledoux, Afumbom, Kfutwa, Faye, Albert, Msellati, Philippe, Warszawski, Josiane, Vos, Alinda, Devillé, Walter, Barth, Roos, Klipstein-Grobusch, Kerstin, Tempelman, Hugo, Venter, François, Coutinho, Roel, Grobbee, Diederick, Ssemwanga, Deogratius, Lyagoba, Frederick, Magambo, Brian, Kapaata, Anne, Kirangwa, Joseph, Nannyonjo, Maria, Nassolo, Faridah, Nsubuga, Rebecca, Yebra, Gonzalo, Brown, Andrew, Kaleebu, Pontiano, Nylén, Hanna, Habtewold, Abiy, Makonnen, Eyasu, Yimer, Getnet, Burhenne, Jürgen, Diczfalusy, Ulf, Aklillu, Eleni, Steele, Duncan, Walker, Richard, Simuyandi, Michelo, Beres, Laura, Bosomprah, Samuel, Ansumana, Rashid, Taitt, C., Lamin, J.M., Jacobsen, K.H., Mulvaney, S.P., Leski, T., Bangura, U., Stenger, D., Vries, Sophie De, Zinsou, Frejus Jeannot, Honkpehedji, J, Dejon, Jean Claude, Loembe, Marguerite Massinga, Bache, Bache, Pakker, Nadine, Leeuwen, Remko Van, Hounkpatin, Aurore Bouyoukou, Yazdanbakhsh, Maria, Bethony, Jeffrey, Hotez, Peter, Diemert, David, Bache, Bache Emmanuel, Fernandes, José F., Mba, Régis M Obiang, Kabwende, Anita L., Grobusch, Martin P., Krishna, Sanjeev, Kremsner, Peter G., Todagbe, Agnandji Selidji, Nambozi, Michael, Kabuya, Jean-Bertin, Hachizovu, Sebastian, Mwakazanga, David, Kasongo, Webster, Buyze, Jozefien, Mulenga, Modest, Geertruyden, Jean-Pierre, Gitaka, Jesse, Chan, Chim, Kongere, James, Kagaya, Wataru, Kaneko, Akira, Kabore, Naomie, Barry, Nouhoun, Kabre, Zachari, Werme, Karidia, Fofana, Aminata, Compaore, Daniel, Nikiema, Frederic, Some, Fabrice, Djimde, Abdoulaye, Zongo, Issaka, Ouedraogo, Bosco, Kone, Aminatou, Sagara, Issaka, Björkman, Anders, Gil, Jose Pedro, Nchinda, Godwin, Bopda, Alain, Nji, Nadesh, Ambada, Georgia, Ngu, Loveline, Tchadji, Jules, Sake, Carol, Magagoum, Suzanne, Njambe, Ghislain D., Lisom, Abel, Park, Chae Gyu, Tait, Dereck, Sibusiso, Hlatjwako, Manda, Olga, Croucher, Kristin, Westhuizen, Anja Van Der, Mshanga, Isaac, Levin, Jonathan, Nanvubya, Annet, Kibengo, Freddie, Jaoko, Walter, Pala, Pietro, Perreau, Matthieu, Namuniina, Annemarie, Kitandwe, Paul, Tapia, Gonzalo, Serwanga, Jennifer, Yates, Nicole, Fast, Pat, Mayer, Bryan, Montefiori, David, Tomaras, Georgia, Robb, Merlin, Lee, Carter, Wagner, Ralf, Sanders, Edward, Kilembe, William, Kiwanuka, Noah, Gilmour, Jill, Kuipers, Hester, Vooij, Dani, Chinyenze, Kundai, Priddy, Frances, Ding, Song, Hanke, Tom, Pantaleo, Giuseppe, Ngasala, Billy, Jovel, Irina, Malmberg, Maja, Mmbando, Bruno, Premji, Zul, Mårtensson, Andreas, Mwaiswelo, Richard, Agbor, Lenshina, Apinjoh, Tobias, Mwanza, Sydney, Chileshe, Justin, Joshi, Sudhaunshu, Malunga, Phidelis, Manyando, Christine, Laufer, Miriam, Dara, Antoine, Niangaly, Amadou, Sinha, Indranil, Brodin, David, Fofana, Bakary, Dama, Souleymane, Dembele, Demba, Sidibe, Bakary, Diallo, Nouhoum, Thera, Mahamadou, Wright, Karin, Gil, Jose, Doumbo, Ogobara, Baraka, Vito, Nabasumba, Carolyn, Francis, Filbert, Lutumba, Pascal, Mavoko, Hypolite, Alifrangis, Michael, Geertruyden, Jean-Pierre Van, Sissoko, Sekou, Sangaré, Cheick, Toure, Sekou, Sanogo, Kassim, Diakite, Hamadoun, Toure, Siaka, Doumbia, Diagassan, Haidara, Kadiatou, Julé, Amélie, Ashurst, Hazel, Merson, Laura, Olliaro, Piero, Marsh, Vicki, Lang, Trudie, Guérin, Philippe, Awuondo, Kennedy, Njenga, Daniel, Nyakarungu, Elizabeth, Titus, Pauline, Sutamihardja, Awalludin, Lowe, Brett, Ogutu, Bernhards, Billingsley, Peter, Soulama, Issiaka, Kaboré, Moïse, Coulibaly, Aboubacar, Ouattara, Maurice, Sanon, Souleymane, Diarra, Amidou, Bougouma, Edith, Ouedraogo, Alphonse, Sombie, Benjamin, Ouedraogo, Amidou, Kargougou, Désiré, Ouattara, Daouda, Issa, Nebie, Tiono, Alfred, Sirima, Sodiomon, Chaponda, Mike, Dabira, Edgard, Dao, François, Dara, Nianwalou, Sidibe, Bouran, Coulibaly, Moctar, Tolo, Allaye, Maiga, Hamma, Ouologuem, Nouhoum, Niangaly, Hamidou, Botchway, Felix, Wilson, Nana, Dickinson-Copeland, Carmen M, Adjei, Andrew A., Wilson, Michael, Stiles, Jonathan K., Hamid, Muzamil Abdel, Awad-Elgeid, Mona, Nasr, Awad, Netongo, Palmer, Kamdem, Séverin, Velavan, Thirumalaisamy, Lasry, Estrella, Diarra, Modibo, Bamadio, Amadou, Traore, Aliou, Coumare, Samba, Soma, Bahonan, Dicko, Yeyia, Sangare, Boubou, Tembely, Aly, Traore, Djibril, Haidara, Aboubecrin, Dicko, Alassane, Diawara, Elisabeth, Beavogui, Abdoul, Camara, Daouda, Sylla, Malick, Yattara, Mohamed, Sow, Amadou, Camara, Gnèpou Camara, Diallo, Saliou, Mombo-Ngoma, Ghyslain, Remppis, Jonathan, Sievers, Moritz, Manego, Rella Zoleko, Endamne, Lilian, Hutchinson, David, Held, Jana, Supan, Christian, Salazar, Carmen L. Ospina, Bonkian, Léa Nadège, Nahum, Alain, Sié, Ali, Abdulla, Salim, Cantalloube, Cathy, Djeriou, Elhadj, Bouyou-Akotet, Marielle, Mordmüller, Benjamin, Siribie, Mohamadou, Sirima, Sodiomon B., Ouattara, San Maurice, Coulibaly, Sam, Kabore, Jean Moïse, Amidou, Diarra, Tekete, Mamadou, Burhenne, Juergen, Traore, Oumar, Haefeli, Walter, Borrmann, Steffen, Kaboré, Naomie, Kabré, Zachari, Nikèma, Fréderic, Compaoré, Daniel, Somé, Fabrice, Djimdé, Abdoulaye, Ouédraogo, Jean, Chalwe, Victor, Miller, John, Diakité, Hamadoun, Greco, Beatrice, Spangenberg, Thomas, Kourany-Lefoll, Elly, Oeuvray, Claude, Mulry, Jim, Tyagarajan, Kamala, Magsaam, Bettina, Barnes, Karen, Hodel, Eva Maria, Humphreys, Georgina, Pace, Cheryl, Banda, C.G, Denti, Paulo, Allen, Elizabeth, Lalloo, David, Mwapasa, Victor, Terlouw, Anja, Mwesigwa, Julia, Achan, Jane, Jawara, Musa, Ditanna, Gian, Worwui, Archibald, Affara, Muna, Koukouikila-Koussounda, Félix, Kombo, Michael, Vouvoungui, Christevy, Ntoumi, Francine, Etoka-Beka, Mandingha Kosso, Deibert, Julia, Poulain, Pierre, Kobawila, Simon, Gueye, Nerly Gampio, Koukouikila-Koussounda, Felix, Seda, Brian, Kwambai, Titus, Jangu, Phelix, Samuels, Aaron, ter Kuile, Feike, Kariuki, Simon, Barry, Aissata, Bousema, Teun, Okech, Brenda, Egwang, Thomas, Corran, Patrick, Riley, Eleanor, Ezennia, Ifeoma, Ekwunife, Obinna, Muleba, Mbanga, Stevenson, Jennifer, Mbata, Keith, Coetzee, Maureen, Norris, Douglas, Moneke-Anyanwoke, Ngozi, Momodou, Jasseh, Clarke, Ed, Scott, Susana, Tijani, Adelani, Djimde, Moussa, Vaillant, Michel, Samouda, Hanen, Mensah, Victorine, Roetynck, Sophie, Kanteh, Ebrima, Bowyer, Georgina, Ndaw, Amy, Oko, Francis, Bliss, Carly, Jagne, Ya Jankey, Cortese, Riccardo, Nicosia, Alfredo, Roberts, Rachel, D'Alessio, Flavia, Leroy, Odile, Faye, Babacar, Cisse, Badara, Gerry, Stephen, Viebig, Nicola, Lawrie, Alison, Ewer, Katie, Hill, Adrian, Nebie, Issa, Tiono, Alfred B, Sanou, Guillaume, Konate, Amadou T, Yaro, Baptiste J, Sodiomon, Sirima, Honkpehedji, Yabo, Agobe, Jean Claude Dejon, Zinsou, Frejus, Mengue, Juliana, Richie, Thomas, Hoffman, Stephen, Nouatin, Odilon, Ngoa, Ulysse Ateba, Edoa, Jean R, Homoet, Andreas, Engelhon, Julie Englhon, Massinga-Louembe, Marguerite, Esen, Meral, Theisen, Michael, Sim, Kim Lee, Luty, Adrian Jf, Moutairou, Kabirou, Dinko, Bismarck, King, Elizabeth, Targett, Geoffrey, Sutherland, Colin, Likhovole, Clement, Ouma, Collins, Vulule, John, Musau, Susan, Khayumbi, Jeremiah, Okumu, Albert, Murithi, Wilfred, Otu, Jacob, Gehre, Florian, Zingue, Dezemon, Kudzawu, Samuel, Forson, Audrey, Mane, Morto, Rabna, Paulo, Diarra, Bassirou, Kayede, Salako, Adebiyi, Emmanuel, Kehinde, Aderemi, Onyejepu, Nneka, Onubogu, Catherine, Idigbe, Emmanuel, Ba, Awa, Diallo, Aissatou, Mboup, Souleymane, Disse, Kodjo, Kadanga, Gerard, Dagnra, Yaotse, Baldeh, Ignatius, Corrah, Tumani, Jong, Bouke De, Antonio, Martin, Musanabaganwa, Clarisse, Musabyimana, Jean Pierre, Karita, Etienne, Diop, Blondin, Nambajimana, Abidan, Dushimiyimana, Valentine, Karame, Prosper, Russell, Jim, Ndoli, Jules, Hategekimana, Theobald, Sendegeya, Augustin, Condo, Jeannine, Binagwaho, Agnes, Okonko, Iheanyi, Okerentugba, Phillip, Opaleye, Oluyinka, Awujo, Ezinwanne, Frank-Peterside, Nnenna, Moyo, Sikhulile, Kotokwe, Kenanao, Mohammed, Terence, Boleo, Coretah, Mupfumi, Lucy, Chishala, Samuel, Gaseitsiwe, Simani, Tsalaile, Lesedi, Bussmann, Herman, Makhema, Joseph, Baum, Marianna, Marlink, Richard, Engelbretch, Susan, Essex, Max, Novitsky, Vladimir, Saka, Emmanuel, Kalipalire, Zex, Bhairavabhotla, Ravikiran, Midiani, Dalitso, Sherman, Judith, Mgode, Georgies, Cox, Christophe, Bwana, Dickens, Mtui, Leah, Magesa, Daniel, Kahwa, Amos, Mfinanga, Godfrey, Mulder, Christiaan, Borain, Nick, Petersen, Lizette, Plessis, Julianne Du, Theron, Grant, Holm-Hansen, Carol, Tekwu, Emmanuel Mouafo, Sidze, Larissa Kamgue, Assam, Jean Paul Assam, Eyangoh, Sarah, Niemann, Stefan, Beng, Veronique Penlap, Frank, Matthias, Atiadeve, Samuel, Hilmann, Doris, Awoniyi, Dolapo, Baumann, Ralf, Kriel, Belinda, Jacobs, Ruschca, Kidd, Martin, Loxton, Andre, Kaempfer, Susanne, Singh, Mahavir, Mwanza, Winnie, Milimo, Deborah, Moyo, Maureen, Kasese, Nkatya, Cheeba-Lengwe, Maina, Munkondya, Stembiso, Ayles, Helen, Haas, Petra De, Muyoyeta, Monde, Namuganga, Anna Ritah, Kizza, Harriet Mayanja, Mendy, Alieu, Tientcheu, Leopold, Ayorinde, Abigail, Coker, Edward, Egere, Uzochukwu, Coussens, Anna, Naude, Celeste, Chaplin, George, Noursadeghi, Mahdad, Martineau, Adrian, Jablonski, Nina, Wilkinson, Robert, Ouedraogo, Henri Gautier, Matteelli, Alberto, Regazzi, Mario, Tarnagda, Grissoum, Villani, Paola, Sulis, Giorgia, Diagbouga, Serge, Roggi, Alberto, Giorgetti, Francesco, Kouanda, Seni, Bidias, Amel, Ndjonka, Dieudonné, Olemba, Clémence, Souleymanou, Arabo, Mukonzo, Jackson, Kuteesa, Ronald, Ogwal-Okeng, Jasper, Gustafsson, Lars L., Owen, Joel, Bassi, Peter, Gashau, Wadzani, Olaf, Klungel, Dodoo, Alexander, Okonkwo, Prosper, Kanki, Phyllis, Maruapula, Dorcas, Seraise, Boitumelo, Einkauf, Kevin, Reilly, Amanda, Rowley, Christopher, Musonda, Rosemary, Framhein, Anna, Mpagama, Stella, Semvua, Hadija, Maboko, Leonard, Hoelscher, Michael, Heinrich, Norbert, Mulenga, Lloyd, Kaayunga, Callistus, Davies, Mary-Ann, Egger, Matthias, Musukuma, Kalo, Dambe, Rosalia, Usadi, Benjamin, Ngari, Moses, Thitiri, Johnstone, Mwalekwa, Laura, Fegan, Greg, Berkley, James, Nsagha, Dickson, Munamunungu, Virginia, Bolton, Carolyn, Siyunda, Alice, Shilimi, Jacinta, Bucciardini, Raffaella, Fragola, Vincenzo, Abegaz, Teshome, Lucattini, Stefano, Halifom, Atakilt, Tadesse, Eskedar, Berhe, Micheal, Pugliese, Katherina, Castro, Paola De, Terlizzi, Roberta, Fucili, Luca, Gregorio, Massimiliano Di, Mirra, Marco, Zegeye, Teame, Binelli, Andrea, Vella, Stefano, Abraham, Loko, Godefay, Hagos, Rakotoarivelo, Rivo, Raberahona, Mihaja, Randriamampionona, Njary, Andriamihaja, Rabezanahary, Rasamoelina, Tahinamandranto, Cornet, Muriel, Randria, Mamy Jean De Dieu, Benet, Thomas, Vanhems, Philippe, Andrianarivelo, Mala Rakoto, Chirwa, Uchizi, Michelo, Charles, Hamoonga, Raymond, Wandiga, Steve, Oduor, Patience, Agaya, Janet, Sharma, Aditya, Cavanaugh, Sean, Cain, Kevin, Mukisa, John, Mupere, Ezekiel, Worodria, William, Ngom, Justice Trésor, Koro, Francioli, Godwe, Celestin, Adande, Clemence, Ateugieu, Romaric, Onana, Tatiana, Ngono, Annie, Kamdem, Yannick, Ngo-Niobe, Sara, Etoa, François-Xavier, Kanengoni, Muchineripi, Ruzario, Sithembile, Ndebele, Paul, Shana, Melody, Tarumbiswa, Fadzai, Musesengwa, Rosemary, Gutsire, Rutendo, Fisher, Kevin, Thyagarajan, Bargavi, Akanbi, Olusola, Binuyo, Michael, Ssengooba, Willy, Respeito, Durval, Mambuque, Edson, Blanco, Silvia, Mandomando, Inacio, Cobelens, Frank, Garcia-Basteiro, Alberto, Tamene, Ayele, Topp, Stephanie, Mwamba, Chanda, Padian, Nancy, Sikazwe, Izukanji, Geng, Elvin, Holmes, Charles, Sikombe, Kombatende, Hantuba, Cardinal, Czaicki, Nancy, Simbeza, Sandra, Somwe, Paul, Umulisa, Michele, Ilo, Jennifer, Kestelyn, Evelyne, Uwineza, Mireille, Agaba, Stephen, Delvaux, Therese, Wijgert, Janneke, Gethi, Dickson, Odeny, Lazarus, Tamandjou, Cynthia, Kaindjee-Tjituka, Francina, Brandt, Laura, Cotton, Mark, Nel, Etienne, Preiser, Wolfgang, Andersson, Monique, Adepoju, Abiola, Magana, Musa, Etsetowaghan, Andrew, Chilikwazi, Mutinta, Sutcliffe, Catherine, Thuma, Philip, Sinywimaanzi, Kathy, Matakala, Hellen, Munachoonga, Passwell, Moss, William, Masenza, Issa Sabi, Geisenberger, Otto, Agrea, Peter, Rwegoshora, France, Mahiga, Hellen, Olomi, Willyhelmina, Kroidl, Arne, Kayode, Gbenga, Amoakoh-Coleman, Mary, Ansah, Evelyn, Uthman, Olalekan, Fokam, Joseph, Santoro, Maria-Mercedes, Musolo, Chrissie, Chimbiri, Isabel, Chikwenga, Gloria, Deula, Ruth, Massari, Riccardo, Lungu, Agness, Perno, Carlo-Federico, Ndzengue, Georgia, Loveline, Ngu, Lissom, Abel, Flaurent, Tchouangueu, Sosso, Samuel, Essomba, Claudine, Kpeli, Grace, Otchere, Isaac, Lamelas, Araceli, Buultjens, Andrew, Bulach, Dieter, Baines, Sarah, Seemann, Torsten, Giulieri, Stefano, Nakobu, Zuliehatu, Aboagye, Samuel, Owusu-Mireku, Evelyn, Danso, Emelia, Hauser, Julia, Hinic, Vladimira, Pluschke, Gerd, Stinear, Timothy, Yeboah-Manu, Dorothy, Elshayeb, Ayman, Siddig, Marmar El, Ahmed, Abdel Azim, Hussien, Adil El, Kabwe, Mwila, Tembo, John, Chilukutu, Lophina, Chilufya, Moses, Ngulube, Francis, Lukwesa, Chileshe, Enne, Virve, Wexner, Hannah, Mwananyanda, Lawrence, Hamer, Davidson, Sinyangwe, Sylvester, Ahmed, Yusuf, Klein, Nigel, Maeurer, Markus, Zumla, Ali, Bates, Matthew, Beyala, Landry, Etienne, Guenou, Anthony, Njimbia, Benjamin, Azike, Ateudjieu, Jerome, Chibwe, Bertha, Ojok, David, Tarr, Christine Attia, Perez, Guillermo Martinez, Omeonga, Senga, Kibungu, Fanta, Meyer, Ana, Lansana, Peter, Mayor, Alfredo, Onyango, Peter, Loggerenberg, François Van, Furtado, Tamzin, Boggs, Liam, Segrt, Alexis, Dochez, Carine, Burnett, Rosemary, Mphahlele, M. Jeffrey, Miiro, George, Mbidde, Edward, Peshu, Norbert, Kivaya, Esther, Ngowi, Bernard, Kavishe, Reginald, Maowia, Mukhtar, Sandstrom, Eric, Ayuo, Elizabeth, Mmbaga, Blandina, Leisegang, Cordelia, Thorpe, Marie, Batchilly, Elizabeth, N'Guessan, Jean-Pierre, Kanteh, Dembo, Søfteland, Solrun, Sebitloane, Motshedisi, Vwalika, Bellington, Taylor, Myra, Galappaththi-Arachchige, Hashini, Holmen, Sigve, Gundersen, Svein Gunnar, Ndhlovu, Patricia, Kjetland, Eyrun Floerecke, Kombe, Francis, Toohey, Jacintha, Pienaar, Elizabeth, Kredo, Tamara, Cham, Pa Modou, Abubakar, Ismaela, Dondeh, Bai Lamin, Vischer, Nerina, Pfeiffer, Constanze, Burri, Christian, Musukwa, Kalo, Zürcher, Samuel, Mwandu, Temwani, Bauer, Sophie, Adriko, Moses, Mwaura, Peter, Omolloh, Kevin, Jones, Clarer, Malecela, Mwelecele, Hamidu, Buhari Adamu, Jenner, Tettevi Edward, Asiedu, Larbi John, Osei-Atweneboana, Mike, Afeke, Innocent, Addo, Phyllis, Newman, Mercy, Durnez, Lies, Eddyani, Miriam, Ammisah, Nana, Abas, Mona, Quartey, Maxwell, Ablordey, Anthony, Akinwale, Olaoluwa, Adeneye, Adeniyi, Ezeugwu, Sylvanus, Olukosi, Yetunde, Adewale, Babatunde, Sulyman, Medinat, Mafe, Margaret, Okwuzu, Jane, Gyang, Pam, Nwafor, Timothy, Henry, Uzoma, Musa, Bilkisu, Ujah, Innocent, Agobé, Jean Claude Dejon, Grau-Pujol, Berta, Sacoor, Charfudin, Nhabomba, Augusto, Casellas, Aina, Quintó, Llorenç, Subirà, Carme, Giné, Ricard, Valentín, Antònia, Muñoz, Jose, Nikiema, Marguerite, Ky-Ba, Absatou, Comapore, Kiswendsida Abdou Muller, Traore, Alfred, Sangare, Lassana, Oluremi, Adeolu, Michel, Mandro, Camara, Yaya, Sanneh, Bakary, Cuamba, Inocencia, Gutiérrez, Jose, Lázaro, Carlota, Mejia, Rojelio, Adedeji, Abimbola, Folorunsho, Sola, Demehin, Pelumi, Akinsanya, Bamidele, Cowley, Giovanna, Silva, Eunice Teixeira Da, Nabicassa, Meno, Barros, Pedrozinho Duarte Pereira De, Blif, Milena Mbote, Bailey, Robin, Last, Anna, Mahendradhata, Yodi, Gotuzzo, Eduardo, Nys, Kateljine De, Casteels, Minnes, Nona, Sylvie Kwedi, Lumeka, Kabwende, Todagbe, Agnandji, Djima, Mariam Mama, Ukpong, Morenike, Sagay, Atiene, Khamofu, Hadiza, Torpey, Kwasi, Afiadigwe, Evaristus, Anenih, James, Ezechi, Oliver, Nweneka, Chidi, Idoko, John, Muhumuza, Simon, Katahoire, Anne, Nuwaha, Fred, Olsen, Annette, Okeyo, Seth, Omollo, Raymond, Kimutai, Robert, Ochieng, Michael, Egondi, Thaddaeus, Moonga, Clement, Chileshe, Chisele, Magwende, George, Anumudu, Chiaka, Onile, Olugbenga, Oladele, Victoria, Adebayo, Adewale, Awobode, Henrietta, Oyeyemi, Oyetunde, Odaibo, Alexander, Kabuye, Emily, Lutalo, Tom, Njua-Yafi, Clarisse, Nkuo-Akenji, Theresa, Anchang-Kimbi, Judith, Mugri, Regina, Chi, Hanesh, Tata, Rolland, Njumkeng, Charles, Dodoo, Daniel, Achidi, Eric, Fernandes, José, Bache, Emmanuel B., Matakala, Kalumbu, Searle, Kelly, Greenman, Michelle, and Rainwater-Lovett, Kaitlin

Subjects
Abstracts of Poster Presentations, Abstracts of Oral Presentations, Author Index, Abstracts of Presentations in Plenary Sessions, Article, Abstracts of the Eighth Edctp Forum, 6–9 November 2016
Published
2017

2. Enhancing science preparedness for health emergencies in Africa through research capacity building

Author

Kinyanjui, Sam, primary, Fonn, Sharon, additional, Kyobutungi, Catherine, additional, Vicente-Crespo, Marta, additional, Bonfoh, Bassirou, additional, Ndungu, Thumbi, additional, Sewankambo, Nelson Kaulukusi, additional, Djimde, Abdoulaye A, additional, Gaye, Oumar, additional, Chirwa, Tobias, additional, Musenge, Eustasius, additional, Elliot, Alison, additional, Nakanjako, Damalie, additional, Chibanda, Dixon, additional, and Awandare, Gordon, additional

Published
2020
Full Text
View/download PDF

3. PO 8269 SELECTION OF SEVEN-MUTATION PFCRT-PFMDR1 GENOTYPE AFTER SCALING-UP SEASONAL MALARIA CHEMOPREVENTION WITH SULPHADOXINE-PYRIMETHAMINE AND AMODIAQUINE IN MALI

Author

Maiga, Hamma, primary, Bamadio, Amadou, additional, Traore, Aliou, additional, Diallo, Nouhoum, additional, Diarra, Modibo, additional, Sagara, Issaka, additional, Niangaly, Hamidou, additional, Coumare, Samba, additional, Sangare, Boubou, additional, Traore, Djibril, additional, Vaillant, Michel, additional, Dicko, Alassane, additional, Doumbo, Ogobara K, additional, and Djimde, Abdoulaye, additional

Published
2019
Full Text
View/download PDF

5. OC 8721 WANECAM II – A CLINICAL TRIAL PROGRAMME TO ASSESS SAFETY, EFFICACY AND TRANSMISSION-BLOCKING PROPERTIES OF A NEW ANTIMALARIAL KAF156 (GANAPLACIDE) IN UNCOMPLICATED MALARIA IN WEST AND CENTRAL AFRICA

Author

Jean-Bosco Ouedraogo, Aminata Fofana, Aminatou Kone, Ghyslain Mombo-Ngoma, Issiaka Soulama, Abdoulaye Djimde, David Hughes, Sophie Biguenet, José Pedro Gil, Sodiomon B. Sirima, Cornelis Winnips, Laurent Dembele, Eric Adehossi, Edithe Ilboudo-Sanogo, Stéphane Picot, Anders Björkman, Issaka Sagara, Bakary Fofana, Rella Zoleko Manego, Steffen Borrmann, Alassane Dicko, Colin J. Sutherland, Ogobara K. Doumbo, Martin P. Grobusch, Issaka Zongo, and Stephan Duparc

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public health, Public Health, Environmental and Occupational Health, Capacity building, Context (language use), medicine.disease, Lumefantrine, Clinical trial, chemistry.chemical_compound, chemistry, Drug development, medicine, Artemisinin, Intensive care medicine, business, Malaria, medicine.drug
Abstract

BackgroundDespite major progress in the past decade, malaria remains a major public health problem in sub-Saharan Africa. West and Central Africa account for nearly 2/3 of the burden currently attributable to falciparum malaria. Artemisinin-based combination therapies (ACT) are a cornerstone of our strategy for controlling and eventually eliminating malaria. However, reduced responsiveness/resistance to artemisinin derivatives and to ACTs, an increasing problem in South-East Asia is a major concern. It is of utmost importance to develop new antimalarial drugs from novel chemical classes that can replace ACTs. KAF156, an imidazolepiperazine, is a leading candidate in the antimalarial drug development pipeline. Combination of KAF156 with a Solid Dispersion Formulation of lumefantrine (LUM-SDF) is expected to be fast acting, fully curative, improve patient adherence and can potentially reduce malaria transmission.MethodsWANECAM II proposes to advance the clinical development of KAF156 through clinical trials in adults and children, with integrated capacity building and infrastructure development activities. The trial programme will be undertaken in the context of networking, team-building, leadership development and community engagement schemes that will involve intra-European, European-African and intra-African collaborative activities. WANECAM II will accelerate the clinical study of children less than 2 years of age which are the key target for new antimalarial treatments.ResultsBy the end of the project, the results are expected to contribute to the registration of KAF156/LUM-SDF through stringent regulatory health authorities, increase biomedical research capacity in the consortium and effectively promote networking among the respective teams. A new clinical research team in Niger, a grossly underrepresented country in the African research landscape, will be developed and further increase capacity and infrastructure in the consortium.ConclusionProviding a new antimalarial drug combination that does not contain an artemisinin derivative and is effective against resistant P. falciparum strains as well as gametocytes and that is likely to be taken in 3 or fewer single doses will be a major advance in the field. The new combination of KAF156 with LUM-SDF is expected to provide such major advance upon successful conclusion of the WANECAM II project.

Published
2019
Full Text
View/download PDF

6. PO 8269 SELECTION OF SEVEN-MUTATION PFCRT-PFMDR1 GENOTYPE AFTER SCALING-UP SEASONAL MALARIA CHEMOPREVENTION WITH SULPHADOXINE-PYRIMETHAMINE AND AMODIAQUINE IN MALI

Author

Hamma Maiga, Abdoulaye Djimde, Alassane Dicko, Modibo Diarra, Djibril Traore, Aliou Traore, Ogobara K. Doumbo, Amadou Bamadio, Samba Coumare, Nouhoum Diallo, Boubou Sangare, Issaka Sagara, Michel Vaillant, and Hamidou Niangaly

Subjects
Mutation, education.field_of_study, Health Policy, Population, Public Health, Environmental and Occupational Health, Plasmodium falciparum, Amodiaquine, Biology, medicine.disease_cause, biology.organism_classification, medicine.disease, Virology, Molecular analysis, Sulphadoxine-pyrimethamine, Genotype, medicine, education, Malaria, medicine.drug
Abstract

BackgroundWHO recommended seasonal malaria chemoprevention (SMC) in 2012 for Sahel countries in Africa with the aim to reduce malaria among children under 5 years old by using sulphadoxine-pyrimethamine and amodiaquine (SP+AQ). This strategy was scaled up in Mali from 2012. The use of millions of doses of SP+AQ could generate potential Plasmodium falciparum resistance in mutant parasites. The aim of this study was to monitor the prevalence of Pfdhfr +Pfdhps+pfcrt +pfmdr1 mutations in parasites infecting the target population.MethodsTwo cross-sectional surveys were conducted before (August 2012, n=662) and after (June 2014, n=670) a pilot implementation of SMC in the health district of Koutiala. Children aged 3–59 months received 3 and 4 rounds of curative doses of SP+AQ over two malaria seasons in 2012 and 2013, respectively. Genotypes of P. falciparum Pfdhfr codons 51, 59, 108 and 164; Pfdhps codons 437 and 540, Pfcrt codon 76 and Pfmdr1 codon 86 were analysed by PCR on DNA of parasites from SMC population blood samples (after and before) and non-SMC patients aged 7 years or above (November 2014, n=500).ResultsIn the SMC population 191 and 85 children before and after SMC implementation, respectively, were included in’the molecular analysis. In the non-SMC patients, 220 were’successfully PCR analysed. In the SMC population, the’prevalence of the six-mutation Pfcrt [Pfdhfr-dhps quintuple +Pfcrt-76T] genotype increased significantly after SMC implementation, from 0.0% to 7.1% (p=0.0008). The post-intervention prevalence of the six-mutation Pfmdr1 [Pfdhfr-dhps quintuple +Pfmdr1–86Y] and the seven-mutation Pfcrt +Pfmdr1 [Pfdhfr-dhps quintuple +Pfmdr1–86Y+Pfcrt-76T] genotypes were both 1.2% among the SMC population. No six-mutation and seven-mutation genotypes were observed among SMC population at baseline nor in the non-SMC patient population (p=0.30).ConclusionSMC increased the prevalence of the six-mutation Pfcrt genotype of P. falciparum that can lead to resistance in a population exposed to SMC with SP+AQ.

Published
2019
Full Text
View/download PDF

8. PF3D7_1343700 KELCH PROPELLER (K13-PROPELLER) POLYMORPHISMS AND ARTESUNATE MONOTHERAPY EFFICACY IN UNCOMPLICATED MALARIA TREATMENT IN MALI

Author

Sissoko, Sekou, primary, Kone, Aminatou, additional, Fofana, Bakary, additional, Sangaré, Cheick, additional, Dembele, Demba, additional, Toure, Sekou, additional, Sanogo, Kassim, additional, Diakite, Hamadoun, additional, Toure, Siaka, additional, Doumbia, Diagassan, additional, Haidara, Kadiatou, additional, Doumbo, Ogobara, additional, and Djimde, Abdoulaye, additional

Published
2017
Full Text
View/download PDF

9. RANDOMIZED TRIAL TO ASSESS EFFECT OF REPEATED TREATMENT OF DHA-PQ AND AL ON QTC INTERVAL IN PATIENTS PRESENTING WITH UNCOMPLICATED MALARIA IN BOBO-DIOULASSO, BURKINA FASO

Author

Kabore, Naomie, primary, Barry, Nouhoun, additional, Kabre, Zachari, additional, Werme, Karidia, additional, Fofana, Aminata, additional, Compaore, Daniel, additional, Nikiema, Frederic, additional, Some, Fabrice, additional, Djimde, Abdoulaye, additional, Zongo, Issaka, additional, and Ouedraogo, Bosco, additional

Published
2017
Full Text
View/download PDF

10. IMPACT OF TREATMENT OF UNCOMPLICATED MALARIA BY AMODIAQUINE−ARTESUNATE (AS-AQ) ON PFCRT 76T AND PFMDR1 86Y MUTATIONS SELECTION INPLASMODIUM FALCIPARUMISOLATES, REPUBLIC OF GUINEA

Author

Diawara, Elisabeth, primary, Beavogui, Abdoul, additional, Camara, Daouda, additional, Sylla, Malick, additional, Yattara, Mohamed, additional, Sow, Amadou, additional, Camara, Gnèpou Camara, additional, Diallo, Saliou, additional, Doumbo, Ogobara, additional, and Djimde, Abdoulaye, additional

Published
2017
Full Text
View/download PDF

14. EFFECT OF ARTESUNATE MONOTHERAPY ONPLASMODIUM FALCIPARUMIN VIVO GENOMIC EXPRESSION

Author

Kone, Aminatou, primary, Dara, Antoine, additional, Niangaly, Amadou, additional, Sinha, Indranil, additional, Brodin, David, additional, Fofana, Bakary, additional, Dama, Souleymane, additional, Dembele, Demba, additional, Sidibe, Bakary, additional, Diallo, Nouhoum, additional, Thera, Mahamadou, additional, Sagara, Issaka, additional, Wright, Karin, additional, Björkman, Anders, additional, Gil, Jose, additional, Doumbo, Ogobara, additional, and Djimde, Abdoulaye, additional

Published
2017
Full Text
View/download PDF

15. SEASONAL MALARIA CHEMOPREVENTION WITH SULPHADOXINE-PYRIMETHAMINE AND AMODIAQUINE SELECTS DHFR-DHPS QUINTUPLE MUTANT GENOTYPE IN MALI

Author

Maiga, Hamma, primary, Lasry, Estrella, additional, Diarra, Modibo, additional, Sagara, Issaka, additional, Bamadio, Amadou, additional, Traore, Aliou, additional, Coumare, Samba, additional, Soma, Bahonan, additional, Dicko, Yeyia, additional, Diallo, Nouhoum, additional, Sangare, Boubou, additional, Tembely, Aly, additional, Traore, Djibril, additional, Niangaly, Hamidou, additional, Dao, François, additional, Haidara, Aboubecrin, additional, Dicko, Alassane, additional, Doumbo, Ogobara, additional, and Djimde, Abdoulaye, additional

Published
2017
Full Text
View/download PDF

16. RANDOMIZED TRIAL TO ASSESS EFFECT OF REPEATED TREATMENT OF DHA-PQ AND AL ON QTC INTERVAL IN PATIENTS PRESENTING WITH UNCOMPLICATED MALARIA IN BOBO-DIOULASSO, BURKINA FASO

Author

Issaka Zongo, Abdoulaye Djimde, Karidia Werme, Frederic Nikiema, Naomie Kaboré, Nouhoun Barry, Aminata Fofana, Fabrice A. Somé, Zachari Kabré, Bosco Ouedraogo, and Daniel Compaore

Subjects
medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, QT interval, Surgery, law.invention, Repeated treatment, Randomized controlled trial, law, Drug tolerance, Internal medicine, medicine, In patient, Artemisinin, Adverse effect, business, Malaria, medicine.drug
Abstract

Background Artemisinin combination therapies (ACTs) are widely used for the management of malaria and even tested for chemoprevention. In single episode efficacy studies, these drugs were clinically well tolerated but cardiac effects over repeated treatment are less investigated. Methods We conducted a prospective randomised controlled trial in Bobo-Dioulasso from August to October 2013 where patients aged 6 months and over were randomly allocated to receive either dihydroartemisinin-piperaquine (DHAPQ) or artemether-lumefantrine (AL) on first and subsequent episodes. Each participant was screened against inclusion criteria including the ECG which was repeated again 2 hours after the last dose. We considered that a QTc interval more than 30 ms compared to the baseline value is abnormal, but a prolonged QTc interval over 450 ms was reported as adverse event. QTc values were categorised into less or greater or equal to 450 ms. Drug tolerance was compared using Chi-square test, and p-value of less than 0.5 is significant. Results Patients were randomised to receive DHAPQ (n=224) or AL (n=236). During the 2 years follow-up we observed a total of 130 (in 1173 electrocardiogram performed on day 2 monitoring) prolonged QTc more than 450 ms (96/548 for DHAPQ and 34/625 for AL, p Conclusions The proportion of prolonged QTc was higher in DHAPQ group compared to the AL group but decreased along with the number of retreatments. Otherwise, DHAPQ and AL were well tolerated despite repeated treatment of malaria, which seemed to improve over consecutive episodes.

Published
2017
Full Text
View/download PDF

17. COMPARISON OF AUTOMATIC AND MANUAL MEASUREMENT OF QT AND QTC INTERVALS DURING A CLINICAL PHASE III-B/ IV IN KOLLE, MALI

Author

Issaka Sagara, Hamma Maiga, Nouhoum Ouologuem, Hamidou Niangaly, Allaye Tolo, Bouran Sidibe, Nianwalou Dara, Moctar Coulibaly, Abdoulaye Djimde, and François Dao

Subjects
Alternative methods, Prolonged QTc, business.industry, Health Policy, Anesthesia, Public Health, Environmental and Occupational Health, Corrected qt, Medicine, business, QT interval
Abstract

Background The detailed assessment of the QT and corrected QT (QTc) intervals prolongation is recommended when testing new drugs. The electrocardiograph automatically displays generally reliable values of the QT interval and corrected QT but morphological variations of the T wave may cause reading errors, hence the use of the manual measurement as an alternative method. Our objective was to evaluate the correlation between the automatic and manual measurement of QT values. Methods In Kolle from March 2012 to December 2015, an open randomised, phase III-b/IV study comparing dihydroartemisinine-piperaquine, pyronaridine-artesunate and artemether-lumefantrine was conducted. An electrocardiograph cartridge 12 electrodes coupled to a computer with the Tele Touch software was used for the electrocardiogram on Day 0 before the study drugs administration and on Day 2, 2–4 hours after the administration of the last dose of the antimalarial. The manual measurement of QT and QTc was made using the Bazett method [QTcB_m=(Number leaded×0.04×QTcF) / QTcB]. For prolonged QTc cases on Day 2, another measurement was done during the next scheduled visit (Days 7, 14, 21, 28, 35 and 42) until the QTc normalisation. Results A total of 764 ECG was recorded with 398 participants. Different automatic and manual values of QT and QTc are scattered around different medium. Comparisons of different values of QT (p=0.1245) and QTc (p Conclusions Our results indicate no perfect match between automatic and manual methods for QT and QTc. Manual reading remains important to correct any machine errors during clinical studies.

Published
2017
Full Text
View/download PDF

18. PF3D7_1343700 KELCH PROPELLER (K13-PROPELLER) POLYMORPHISMS AND ARTESUNATE MONOTHERAPY EFFICACY IN UNCOMPLICATED MALARIA TREATMENT IN MALI

Author

Ogobara K. Doumbo, Kassim Sanogo, Diagassan Doumbia, Sekou Sissoko, Abdoulaye Djimde, Sekou Toure, Aminatou Kone, Hamadoun Diakite, Cheick Papa Oumar Sangare, Kadiatou Haidara, Demba Dembele, Siaka Toure, and Bakary Fofana

Subjects
medicine.medical_specialty, Direct sequencing, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Context (language use), Single-nucleotide polymorphism, Pharmacology, Uncomplicated malaria, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Blood smear, chemistry, Artesunate, Internal medicine, parasitic diseases, Medicine, 030212 general & internal medicine, business, Dried blood, Prospective cohort study, 030217 neurology & neurosurgery
Abstract

Background Several mutations in the PF3D7_1343700 kelch propeller (K13-propeller) were recently described as associated with artemisinin resistance in vivo and in vitro in Southeast Asia. In Mali, a preliminary study on artesunate efficacy in 2011 found no delay in parasite clearance. A larger study including two sites in Mali is conducted here in the context of regular monitoring of artemisinin resistance. Methods From October 2015 to March 2016, we conducted a prospective study on artesunate monotherapy in Bougoula-Hameau and Faladje on uncomplicated malaria patients aged more than 6 months. Patients were treated for 7 days and followed up for 28 days. Blood smear was performed for parasite evaluation every 8 hours until three consecutive slides were negatives. MSP2, Ca1 and TA99 polymorphisms were used to distinguish new infections from recurrent parasites. The PfK13 mutations were genotyped using direct sequencing of PCR amplicons from dried blood spots of pre and post-treatment falciparum parasites. The results were compared with the studies conducted in a same area on 2011. Results A total of 100 and 120 patients were enrolled in Bougoula-Hameau and Faladje, respectively. The uncorrected adequate clinical and parasitological responses (ACPR) were 92.0% in Bougoula-Hameau and 78.3% in Faladje. After molecular correction, we obtained 100% cACPR in both sites. The prevalence of the non-synonymous single nucleotide polymorphisms (SNPs) K13 was 2% in Bougoula (found only at enrolment) but null in Faladje. However SNPs were 3% and 7% in Bougoula-Hameau and Faladje, respectively. Conclusions Artesunate monotherapy remains effective on P. falciparum in Mali and there are only low levels of PfK13 mutations.

Published
2017
Full Text
View/download PDF

19. EFFECT OF ARTESUNATE MONOTHERAPY ONPLASMODIUM FALCIPARUMIN VIVO GENOMIC EXPRESSION

Author

David Brodin, Karin Dahlman Wright, Antoine Dara, José Pedro Gil, Souleymane Dama, Anders Björkman, Nouhoum Diallo, Ogobara K. Doumbo, Bakary Sidibe, Mahamadou A. Thera, Bakary Fofana, Abdoulaye Djimde, Amadou Niangaly, Issaka Sagara, Demba Dembele, Aminatou Kone, and Indranil Sinha

Subjects
biology, Microarray, Health Policy, Public Health, Environmental and Occupational Health, Anopheles, Plasmodium falciparum, Pharmacology, biology.organism_classification, medicine.disease, Transcriptome, chemistry.chemical_compound, chemistry, Artesunate, parasitic diseases, medicine, Artemisinin, Gene, Malaria, medicine.drug
Abstract

Background Artemisinin-based combination therapies (ACTs) are the main treatment for malaria in endemic countries. Plasmodium falciparum resistance to artemisinins is described as delayed parasite clearance, which is associated with mutations on the parasite K13 propeller gene. Both the mechanisms of action and mechanisms of resistance to artemisinins are poorly understood. Transcriptomic studies can help in improving our understanding of these processes. Here we explore P. falciparum in vivo RNA expression profile after a curative dose of artesunate monotherapy. Methods During a prospective study of the efficacy of artesunate in monotherapy in children aged 1–10 years and presenting uncomplicated P. falciparum malaria in Bougoula-Hameau, Mali, venous blood was collected on PAXgen blood RNA tubes before treatment (H0) and one (H1), two (H2) and three hours (H3) after treatment. RNA was extracted from these respective blood samples and used for microarray experiments with Plasmodium/Anopheles GeneChips and the Affymetrix® platform. Results A total of 23 samples from 6 patients were included in the final analysis after quality control using Affimetrix® and Qlucore® softwares. With a 2-groups comparison of H0/H after treatment, 236 genes were identified as differentially expressed. Overall 42 genes were up-regulated including a knob-associated histidine-rich protein, rifins (pf.12.409.0, pf.13_399.0), stevors (pf.3.184.0), RESA-like proteins with DNAJ domain and thioredoxins. Heat shock protein (Pf.5.258.0), a number of AP2 domain-containing genes (Pf.6.27.0, Pf.11.99.0), an ABC transporter (Pf.12.250.0), genes involved in cell cycle regulation and many exported protein genes with unknown function and membrane proteins genes were among the 194 down-regulated genes. Conclusions Our data support a role for these genes in the in vivo response of P. falciparum to artesunate administration.

Published
2017
Full Text
View/download PDF

20. LUMEFANTRINE DISPOSITION AFTER REPETITIVE TREATMENT OF UNCOMPLICATED MALARIA PATIENTS WITH ARTEMETHER-LUMEFANTRINE IN MALI

Author

Bouran Sidibe, Souleymane Dama, Walter E. Haefeli, Juergen Burhenne, Mamadou Tekete, Nianwalou Dara, Steffen Borrmann, Bakary Fofana, Oumar B Traore, Abdoulaye Djimde, and Sekou Toure

Subjects
Pediatrics, medicine.medical_specialty, Artemether/lumefantrine, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Lumefantrine, Uncomplicated malaria, chemistry.chemical_compound, chemistry, Medicine, In patient, Artemether, Artemisinin, business, Malaria, After treatment, medicine.drug
Abstract

Background Since 2006 the national malaria control program in Mali recommended artemether-lumefantrine (AL) as the first-line treatment of uncomplicated malaria. The role of lumefantrine in this combination is to eliminate remaining parasites after the action of artemether and to protect the patient against a new blood infection. Some studies showed a correlation between lumefantrine9s day 7 concentration and the efficacy of AL after treatment of a single episode of malaria. The objective of this work is to validate this observation after repetitive treatment of uncomplicated malaria patients with AL. Methods During a phase IIIb/IV comparative, randomised, multicentre, clinical study of artemisinin-based combination therapies, we collected plasma on Day 7 from patients treated with standard dose of AL in Sotuba, Bougoula Hameau, and Kolle (Mali). The age of the patients enrolled in this study was from 6 months old. The plasma samples were kept at – 80°C until lumefantrine analysis using high performance liquid chromatography was performed. Results We included 1076 subjects, of which 595 were females and a mean age of 12 years old in this analysis. The median concentration was 66% higher (p vs 372.5 (255.7–538.4; n=157). Day 7 concentrations increased with age; the difference between age group was statistically significant: 305.9 (207.3–491.5, n=140), 447 (290.7–622.9, n=399), 544.7 (383.9–738.5, n=254) and 571.1 (378.8–850.9), n=283) in patients under 5 years old, 5–9 years old, 10–14 years old and 15 years old and older, respectively. Girls under 5 years old had a lower lumefantrine concentration at day 7 compared to other age groups of 223.3 ng/ml (159.7–425.6, n=37). Conclusions We found a lower concentration of lumefantrine in patients with recurrent parasitaemia at day 28.

Published
2017
Full Text
View/download PDF

21. PATTERNS OF MOLECULAR MARKERS OF RESISTANCE IN ‘REAL LIFE’ REPETITIVE DIHYDROARTEMISININ-PIPERAQUINE MALARIA TREATMENT: A MOLECULAR ANALYSIS OF THE WANECAM CLINICAL TRIAL PLATFORM OUTPUT

Author

Aminatou Kone, José Pedro Gil, Abdoulaye Djimde, Anders Björkman, and Issaka Sagara

Subjects
Oncology, medicine.medical_specialty, Kruskal–Wallis one-way analysis of variance, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Context (language use), medicine.disease, Molecular analysis, Clinical trial, Dihydroartemisinin/piperaquine, Internal medicine, Piperaquine, medicine, In real life, business, Malaria
Abstract

Background The pharmacologic characteristic of piperaquine (PPQ), namely its very long half-life, raises concerns on the possibility of relatively rapid rise of resistance. Recent unequivocal reports from SE Asia support this worry. Due to its long half-life, conventional follow-up of up to 63 days in efficacy trials misses the low concentrations of PPQ, prone to select less sensitive parasite sub-populations. The WANECAM clinical trials included a follow-up of two years of the same patients, allowing for the first time the analysis of both, the patterns of selection upon an expected large range of PPQ concentrations and the potential effect of residual levels upon repetitive treatments. Methods We have successfully determined a random sample of E1 (D0) 151 and 405 (E2-E10) pfcrt K76T genotypes, as well as 151 E1 (D0) and 389 (E2-E10) genotypes for the pfmdr1 E2-E10 episodes. Pfmdr1 N86Y analysis was limited by a large (>90%) prevalence of the 86N allele. Established PCR-RFLP methods were applied, with high precision band analysis being performed through image analysis software (GelEval®). Qui Square and Kruskal Wallis tests were used as applicable. Results The present data analysis was limited to episodes with an intervening period of Conclusions Long-term analysis of molecular markers throughout repetitive treatments is expected to unveil informative patterns concerning early steps of PPQ resistance development. The complete set of data will be presented and analysed in the context of the recent findings of PPQ resistance in SE Asia. Its relevance for the East African settings will be discussed.

Published
2017
Full Text
View/download PDF

22. TIME TO SECOND AND THIRD EPISODES OF MALARIA OF DIHYDROARTEMISININ−PIPERAQUINEVSARTESUNATE−AMODIAQUINE AND ARTESUNATE−PYRONARIDINEVSARTEMETER−LUMEFANTRINE IN BOUGOULA HAMEAU, MALI

Author

Ogobara K. Doumbo, Bakary Fofana, Sekou Toure, Kassim Sanogo, Abdoulaye Djimde, Hamadoun Diakite, and Issaka Sagara

Subjects
Pyronaridine, medicine.medical_specialty, Quinine, business.industry, Health Policy, Artesunate/amodiaquine, Public Health, Environmental and Occupational Health, medicine.disease, Lumefantrine, Surgery, chemistry.chemical_compound, chemistry, Dihydroartemisinin/piperaquine, Artesunate, Internal medicine, parasitic diseases, medicine, Artemisinin, business, Malaria, medicine.drug
Abstract

Background Currently, five artemisinin combination therapies (ACTs) are recommended by WHO for treatment of uncomplicated malaria in Africa. While artemisinin derivatives have a short half-life, the partner drugs give rise to differing durations of post-treatment prophylaxis. The pharmacokinetic and pharmacodynamic properties of drug regimens have implications for the public health benefit of the drugs. The development of new antimalarials is ongoing. The objective of this work is to evaluate the prophylactic effect of artesunate−pyronaridine (Pyramax) and dihydroartemisinin−piperaquine (Eurartesim) vs artemether−lumefantrine (AR_L) and artesunate-amodiaquine (ASAQ), respectively in Bougoula Hameau. Methods Through the phase IIIb/IV clinical trial of the West African Network of clinical trial of antimalarial drugs (WANECAM) in Bougoula hameau (Mali) from January 2012 to December 2013, we evaluated the median time of occurrence for the second and third episodes of malaria on patients aged from 6 months to above. After the first randomisation, any other subsequent episodes of malaria as treated by the same ACT initially taken. Treatment failure before day 28 was treated by quinine. Results Whilst 448 patients were randomised to receive DHA (224) vs ASAQ (224), 428 received PA (214) vs AR_L (214). The median time to second and third episodes of malaria were 116 days and 60.5 with PA versus 82.5 and 56.0 for AR_L, respectively. Otherwise, we found 118 and 98 vs 82.5 and 60 days as median time to second and third episode for DHA-PQP vs AS/AQ, respectively. DHA-PQP highly prolonged the median time to second and third episode as compared to ASAQ (p=0.003 and p Conclusions The ACTs artesunate−pyronaridine and dihydroartemisinine−piperaquine significantly prolonged the median time to second and third episode of malaria as compared to artemether-lumefantrine and artesunate−amodiaquine, respectively.

Published
2017
Full Text
View/download PDF

23. SEASONAL MALARIA CHEMOPREVENTION WITH SULPHADOXINE-PYRIMETHAMINE AND AMODIAQUINE SELECTS DHFR-DHPS QUINTUPLE MUTANT GENOTYPE IN MALI

Author

Hamma Maiga, Nouhoum Diallo, Bahonan Soma, Aliou Traore, Ogobara K. Doumbo, Estrella Lasry, Hamidou Niangaly, Alassane Dicko, Samba Coumare, Issaka Sagara, Aly Tembely, Abdoulaye Djimde, Boubou Sangare, Amadou Bamadio, Aboubecrin Sedhigh Haidara, Modibo Diarra, Djibril Traore, François Dao, and Yeyia Dicko

Subjects
Genetics, education.field_of_study, biology, Health Policy, Population, Public Health, Environmental and Occupational Health, DHPS, Plasmodium falciparum, Amodiaquine, musculoskeletal system, medicine.disease, biology.organism_classification, Virology, parasitic diseases, Genotype, cardiovascular system, medicine, Parasite hosting, education, Gene, Malaria, medicine.drug
Abstract

Background Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP)+amodiaquine (AQ) is being scaled up in countries of the Sahel in West Africa. However, the potential development of Plasmodium falciparum resistance to the respective component drugs is a major concern. Methods Two cross-sectional surveys were conducted before (August 2012) and after (June 2014) a pilot implementation of SMC in Koutiala, Mali. Children aged 3–59 months received 7 rounds of curative doses of SP+AQ over two malaria seasons. Genotypes of P. falciparum dhfr codons 51, 59 and 108; dhps codons 437 and 540, pfcrt codon 76 and pfmdr1codon 86 were analysed by PCR on DNA from samples collected before and after SMC, and in non-SMC controls. Results In the SMC population 191/662 (28.9%) and 85/670 (13.7%) of children were P. falciparum- positive by microscopy and were included in the molecular analysis before (2012) and after SMC implementation (2014), respectively. In the control population 220/310 (71%) were successfully PCR analysed. In the SMC children the prevalence of all molecular markers of SP resistance increased significantly after SMC including the dhfr-dhps quintuple mutant genotype, which was 1.6% before but 7.1% after SMC (p=0.02). The prevalence of Pfmdr1–86Y significantly decreased from 26.7% to 15.3% (p=0.04) while no significant change was seen for pfcrt K76T. In 2014, prevalence of all molecular markers of SP resistance were significantly higher among SMC children compared to the non-SMC control population (p Conclusions SMC increased the prevalence of molecular markers of P. falciparum resistance to SP in the treated children. However, there was no significant flow of these resistance genes into the general parasite population after 2 years and 7 rounds of SMC.

Published
2017
Full Text
View/download PDF

24. TO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OFPLASMODIUMSPP. IN BURKINA FASO

Author

Fréderic Nikèma, Jean Ouédraogo, Aminata Fofana, Zachari Kabré, Daniel Compaore, Fabrice A. Somé, Abdoulaye Djimde, Naomie Kaboré, Nouhoun Barry, and Issaka Zongo

Subjects
Pyronaridine, medicine.medical_specialty, Artemether/lumefantrine, business.industry, Malaria vaccine, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Uncomplicated malaria, Surgery, chemistry.chemical_compound, Repeated treatment, chemistry, Artesunate, Who guidelines, Internal medicine, parasitic diseases, Medicine, business, Malaria, medicine.drug
Abstract

Background No safe and highly effective malaria vaccine is available today. The treatment drugs currently in use remain insufficient. Moreover, resistance to these drugs makes malaria control difficult. The development of new therapeutic drugs is required. This abstract is part of a survey from the WANECAM study entitled ‘Randomised trial to assess the effect of repeated treatment of pyronaridine-artesunate (PA), dihydroartemisinin-piperaquine (DHA-PQ) and artemether-lumefantrine (AL) in patients presenting uncomplicated malaria in Bobo-Dioulasso, Burkina Faso’. We present here the analysis of the first episodes on the therapeutic efficiency of PA compared to AL, which is the first-line antimarial used in Burkina Faso. Methods A total of 448 subjects were randomised to receive treatment (224 subjects in each arm). Malaria diagnosis was assessed by microscopy. Subjects were follow-up during 42 days. Treatment response was measured according to standard of care as per WHO guidelines of 2003. The correction of the cases of treatment failure by molecular biology techniques is under analysis. Results On Day 28, the therapeutic failures were 3.35% in the PA group as against 18,10% for the AL group. On Day 42, a significant increase of the treatment failures in every group is observed with a higher rate in the AL group (31.43%), against 17.22% in the PA group. Conclusions This survey shows that less cases of treatment failure occurred in the patients9 group treated with PA compared to the group treated with AL. These findings contributed to evidence base for a change in malaria treatment policy guidelines for uncomplicated malaria in Burkina Faso.

Published
2017
Full Text
View/download PDF

25. Enhancing science preparedness for health emergencies in Africa through research capacity building

Author

Sam Kinyanjui, Catherine Kyobutungi, Thumbi Ndung’U, Oumar Gaye, Nelson Kaulukusi Sewankambo, Sharon Fonn, Marta Vicente-Crespo, Bassirou Bonfoh, Abdoulaye A Djimde, Tobias Chirwa, Eustasius Musenge, Damalie Nakanjako, Dixon Chibanda, Gordon Awandare, and Alison Elliott

Subjects
Medicine (General), R5-920, Infectious and parasitic diseases, RC109-216
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results